OSEBX1 931,54−0,70 %
EQNR338,10−3,37 %
DNB282,60+0,53 %
MOWI198,90−1,63 %
Brent$98,98−2,26 %
Gold$4 743,80+1,05 %
USD/NOK9,2170−0,89 %
EUR/NOK10,8539−0,66 %
SPX7 365,12+0,00 %
NDX28 599,17+0,00 %
LIVE · 10:18 UTC
2593$0.9558

Herbs Generation Group Holdings Ltd

Miscellaneous Specialty RetailersVerified
Score breakdown
Valuation+27Sentiment+30Missing signals-2
Quality breakdown
Key fields100Profile38Conclusion97AI synthesis40Observations13

The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. With a current ratio of 3.88, the firm maintains strong liquidity, supported by HKD 78.22 million in cash and equivalents. The price-to-book ratio of 0.88 suggests the market values the company below its book value, potentially reflecting concerns over profitability or future growth [doc:HA-latest]. Profitability metrics are weak, with a negative return on equity of -15.96% and a return on assets of -11.85%. These figures fall significantly below the industry median for the Personal Care Products sector, which typically sees positive ROE and ROA. The company reported a net loss of HKD 23.01 million, with operating income also negative at HKD -26.51 million, indicating operational inefficiencies or declining margins [doc:HA-latest]. The company's revenue is concentrated in health supplements, cosmetics, and pet health products, with no disclosed geographic breakdown. However, the lack of segment-specific revenue data limits the ability to assess geographic or product diversification. The absence of a clear geographic exposure profile introduces concentration risk, particularly if demand for these products is sensitive to regional economic conditions [doc:HA-latest]. Growth trajectory appears muted, with the most recent actual revenue of HKD 245.49 million, slightly above the reported revenue of HKD 227.87 million. Analysts have not provided forward-looking revenue or EPS estimates, and the company's operating losses suggest a lack of clear growth drivers. The absence of capex or R&D data further limits visibility into future growth initiatives [doc:, doc:]. Risk factors include the company's negative net income and operating income, which could pressure liquidity if cash reserves are not replenished. The low dilution risk is supported by no immediate filing-based flags, and the company has not issued additional shares recently. However, the negative earnings and weak returns suggest a need for close monitoring of cash flow and capital preservation [doc:HA-latest]. Recent events include the latest financial filing, which disclosed the company's operating losses and weak profitability. No significant regulatory or legal events were identified in the latest disclosures. The absence of recent earnings or strategic announcements suggests a period of operational stagnation or restructuring [doc:HA-latest].

Profile
CompanyHerbs Generation Group Holdings Ltd
Ticker2593.HK
SectorConsumer Cyclicals
BusinessRetailers
Industry groupRetailers
IndustryMiscellaneous Specialty Retailers
AI analysis

Business. Herbs Generation Group Holdings Ltd operates as an investment holding company engaged in the development and sales of health supplement, cosmetics, and pet health products under the 'Herbs' brand and others [doc:HA-latest].

Classification. The company is classified under the Consumer Cyclicals economic sector, Retailers business sector, and Miscellaneous Specialty Retailers industry with a confidence level of 0.92 [doc:verified market data].

The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. With a current ratio of 3.88, the firm maintains strong liquidity, supported by HKD 78.22 million in cash and equivalents. The price-to-book ratio of 0.88 suggests the market values the company below its book value, potentially reflecting concerns over profitability or future growth [doc:HA-latest]. Profitability metrics are weak, with a negative return on equity of -15.96% and a return on assets of -11.85%. These figures fall significantly below the industry median for the Personal Care Products sector, which typically sees positive ROE and ROA. The company reported a net loss of HKD 23.01 million, with operating income also negative at HKD -26.51 million, indicating operational inefficiencies or declining margins [doc:HA-latest]. The company's revenue is concentrated in health supplements, cosmetics, and pet health products, with no disclosed geographic breakdown. However, the lack of segment-specific revenue data limits the ability to assess geographic or product diversification. The absence of a clear geographic exposure profile introduces concentration risk, particularly if demand for these products is sensitive to regional economic conditions [doc:HA-latest]. Growth trajectory appears muted, with the most recent actual revenue of HKD 245.49 million, slightly above the reported revenue of HKD 227.87 million. Analysts have not provided forward-looking revenue or EPS estimates, and the company's operating losses suggest a lack of clear growth drivers. The absence of capex or R&D data further limits visibility into future growth initiatives [doc:, doc:]. Risk factors include the company's negative net income and operating income, which could pressure liquidity if cash reserves are not replenished. The low dilution risk is supported by no immediate filing-based flags, and the company has not issued additional shares recently. However, the negative earnings and weak returns suggest a need for close monitoring of cash flow and capital preservation [doc:HA-latest]. Recent events include the latest financial filing, which disclosed the company's operating losses and weak profitability. No significant regulatory or legal events were identified in the latest disclosures. The absence of recent earnings or strategic announcements suggests a period of operational stagnation or restructuring [doc:HA-latest].
Key takeaways
  • The company's capital structure is conservative, with strong liquidity but weak profitability.
  • Negative returns on equity and assets indicate operational inefficiencies or declining margins.
  • Revenue concentration in health supplements and cosmetics introduces product-specific risk.
  • Growth trajectory is unclear, with no analyst estimates or forward-looking guidance.
  • Low dilution risk is offset by weak financial performance and negative earnings.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$227.9M
Gross profit$157.5M
Operating income-$26.5M
Net income-$23.0M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$194.1M
Total liabilities$50.0M
Total equity$144.2M
Cash & equivalents$78.2M
Long-term debt$22.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$227.9M-$26.5M-$23.0M
FY-1$245.5M$19.8M$13.0M$3.7M
FY-2$251.2M$48.3M$39.5M$43.4M
FY-3$208.0M$33.8M$28.0M$27.7M
FY-4$188.6M$28.3M$23.2M$22.2M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$194.1M$144.2M$78.2M
FY-1$242.0M$187.2M$119.2M
FY-2$141.1M$90.6M$22.5M
FY-3$124.1M$70.1M$12.9M
FY-4$114.1M$51.6M$4.2M
PeriodOCFCapExFCFSBC
FY0
FY-1$37.4M-$5.5M$3.7M
FY-2$37.4M-$4.7M$43.4M
FY-3$32.7M-$2.2M$27.7M
FY-4$24.9M-$4.2M$22.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$0.95
Market cap$126.7M
Enterprise value$70.7M
P/E
Reported non-GAAP P/E
EV/Revenue0.3
EV/Op income
EV/OCF
P/B0.9
P/Tangible book0.9
Tangible book$144.2M
Net cash$56.0M
Current ratio3.9
Debt/Equity0.1
ROA-11.8%
ROE-16.0%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Retailers · cohort 8 companies
Metric2593Activity
Op margin-11.6%9.5% medp25 6.4% · p75 13.1%bottom quartile
Net margin-10.1%8.2% medp25 5.0% · p75 11.1%bottom quartile
Gross margin69.1%35.0% medp25 33.0% · p75 44.8%top quartile
R&D / revenue0.4% medp25 0.4% · p75 0.4%
CapEx / revenue3.4% medp25 2.9% · p75 4.6%
Debt / equity15.0%25.8% medp25 3.1% · p75 69.4%below median
Observations
IR observations
Last actual EPS0.13 HKD
Last actual revenue245,490,000 HKD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 03:54 UTC#5090c552
Market quoteclose HKD 0.95 · shares 0.13B diluted
no public URL
2026-05-02 03:54 UTC#57095ffa
Source: analysis-pipeline (hybrid)Generated: 2026-05-02 03:55 UTCJob: 5c478163